|
|
Beone Medicines Ltd (NASDAQ: ONC) |
|
Price: $361.7800
$3.13 
0.871%
|
| Day's High:
| $370.4800109863281
| Week Perf:
| -2.88 %
|
| Day's Low: |
$ 360.53 |
30 Day Perf: |
12 % |
| Volume (M): |
288,600 |
52 Wk High: |
$ 385.22 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$320.28 |
| Open: |
$364.99 |
52 Wk Low: |
$253.95 |
|
|
| Market Capitalization (Millions $) |
544,489 |
| Shares
Outstanding (Millions) |
1,505 |
| Employees |
12,000 |
| Revenues (TTM) (Millions $) |
5,738 |
| Net Income (TTM) (Millions $) |
513 |
| Cash Flow (TTM) (Millions $) |
2,323 |
| Capital Exp. (TTM) (Millions $) |
190 |
Business Description
The company is a global oncology firm specializing in the discovery and development of cancer treatments, with a focus on hematology and solid tumors. Its portfolio includes therapies such as BRUKINSA, sonrotoclax, and BTK-CDAC for chronic lymphocytic leukemia and other B-cell malignancies. The company is also advancing multiple novel molecular entities targeting solid tumors. It employs a global clinical development model supported by a large in-house team, aiming to accelerate drug development while reducing dependence on contract research organizations.
Company Address: c/o BeOne Medicines I GmbH Basel 4051
Company Phone Number: 685 19 00 Stock Exchange / Ticker: NASDAQ ONC
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Thu, Nov 27 2025 2:03 PM UTC
Biopharmaceutical advances continue to transform the landscape of cancer treatment, offering new hope where traditional therapies have fallen short. In this article, we delve into the latest developments surrounding BeOne Medicines Ltd. s promising oncological agents, sonrotoclax and TEVIMBRA, two compounds set to redefine treatment protocols for various challenging cancer t...
|
| Business Update
Published Thu, Nov 20 2025 3:15 PM UTC
BeOne Medicines: Pioneering Advances in Oncology with Promising Data from ASH 2025 and ESMO 2025 SAN CARLOS, California BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) is poised to maintain its status as a leader in innovative oncology solutions with significant advancements showcased at major medical conferences, including the American Society of Hematology...
|
| Business Update
Published Wed, Nov 19 2025 11:57 AM UTC
In a significant advancement for oncology, BeOne Medicines Ltd., recognized for its innovative approaches in cancer treatment, has recently announced compelling results from its Phase-3 clinical trials. These results underscore the potential of ZIIHERA as the preferred treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, particularly wh...
|
| Business Update
Published Mon, Oct 20 2025 11:59 AM UTC
SAN CARLOS, Calif. , October 22, 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a leading player in global oncology, has made significant strides in lung cancer treatments with its latest presentation at the European Society of Medical Oncology (ESMO) 2025 Congress held in Berlin. The company showcased new data from its two pivotal Phase 3 trials, RATIO...
|
| Business Update
Published Tue, Oct 14 2025 9:19 AM UTC
SAN CARLOS, Calif. BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a pioneering global oncology company, has announced a significant milestone in its clinical development programme. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, an advanced and potentially best-in-class investigational BCL2 inhi...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.34 $ |
| Revenues (TTM) |
3.81 $
|
| Cash Flow (TTM) |
1.54 $ |
| Cash |
3.18 $
|
| Book Value |
3.16 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
478,155 |
| Net
Income per Employee (TTM) |
42,752 |
| Receivable Turnover Ratio (TTM) |
6.68 |
| Inventory Turnover Ratio (TTM) |
1.15 |
| Asset Turnover Ratio (TTM) |
0.76 |
|
|
| Per Share |
|
| Earnings (TTM) |
0.34 $
|
| Revenues (TTM) |
3.81 $ |
| Cash Flow (TTM) |
1.54 $ |
| Cash |
3.18 $
|
| Book Value |
3.16 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Other Revenue |
|
 1.73 % |
of total Revenue |
| Other Revenue Novartis |
|
1.73 % |
of total Revenue |
| Amgen royalty revenue Novartis |
|
1.21 % |
of total Revenue |
| Novartis broad markets revenue Novartis |
|
0.35 % |
of total Revenue |
| Other Novartis |
|
0.17 % |
of total Revenue |
| Product revenue |
|
98.29 % |
of total Revenue |
| Product revenue BRUKINSA |
|
72.35 % |
of total Revenue |
| Product revenue TEVIMBRA |
|
13.63 % |
of total Revenue |
| Product revenue XGEVA |
|
5.94 % |
of total Revenue |
| Product revenue BLINCYTO |
|
2.25 % |
of total Revenue |
| Product revenue KYPROLIS |
|
1.12 % |
of total Revenue |
| Product revenue POBEVCY |
|
0.8 % |
of total Revenue |
| Product revenue Other |
|
2.19 % |
of total Revenue |
| U S - total revenue |
|
51.69 % |
of total Revenue |
| China - total revenue |
|
31.19 % |
of total Revenue |
| Europe - total revenue |
|
12.82 % |
of total Revenue |
| Rest of world - total revenue |
|
4.31 % |
of total Revenue |
| Product revenue U S - total revenue |
|
50.59 % |
of total Revenue |
| Product revenue China - total revenue |
|
30.74 % |
of total Revenue |
| Product revenue Europe - total revenue |
|
12.64 % |
of total Revenue |
| Product revenue Rest of world - total revenue |
|
4.31 % |
of total Revenue |
| Other Revenue U S - total revenue |
|
1.1 % |
of total Revenue |
| Other Revenue China - total revenue |
|
0.45 % |
of total Revenue |
| Other Revenue Europe - total revenue |
|
0.18 % |
of total Revenue |
|
|
0.13%